APA

Gue Y. X., Kanji R., Wellsted D. M., Srinivasan M., Wyatt S. & Gorog D. A. (20201106). Rationale and design of "Can Very Low Dose Rivaroxaban (VLDR) in addition to dual antiplatelet therapy improve thrombotic status in acute coronary syndrome (VaLiDate-R)" study : A randomised trial modulating endogenous fibrinolysis in patients with acute coronary syndrome. : Journal of thrombosis and thrombolysis.

Chicago

Gue Ying X, Kanji Rahim, Wellsted David M, Srinivasan Manivannan, Wyatt Solange and Gorog Diana A. 20201106. Rationale and design of "Can Very Low Dose Rivaroxaban (VLDR) in addition to dual antiplatelet therapy improve thrombotic status in acute coronary syndrome (VaLiDate-R)" study : A randomised trial modulating endogenous fibrinolysis in patients with acute coronary syndrome. : Journal of thrombosis and thrombolysis.

Harvard

Gue Y. X., Kanji R., Wellsted D. M., Srinivasan M., Wyatt S. and Gorog D. A. (20201106). Rationale and design of "Can Very Low Dose Rivaroxaban (VLDR) in addition to dual antiplatelet therapy improve thrombotic status in acute coronary syndrome (VaLiDate-R)" study : A randomised trial modulating endogenous fibrinolysis in patients with acute coronary syndrome. : Journal of thrombosis and thrombolysis.

MLA

Gue Ying X, Kanji Rahim, Wellsted David M, Srinivasan Manivannan, Wyatt Solange and Gorog Diana A. Rationale and design of "Can Very Low Dose Rivaroxaban (VLDR) in addition to dual antiplatelet therapy improve thrombotic status in acute coronary syndrome (VaLiDate-R)" study : A randomised trial modulating endogenous fibrinolysis in patients with acute coronary syndrome. : Journal of thrombosis and thrombolysis. 20201106.